Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older
Tahapan Penelitian : Complete
Sponsor:
PT Etana Biotechnologies Indonesia
Mitra Pelaksana:
PT Tigermed Consulting Indonesia
No Registry
INA-P0HETP2
Tanggal Input Registry : 19-07-2024
Tracking Information | |
---|---|
Tanggal Antisipasi Studi | 01-01-2021 |
Outcome Primer | not specified |
Outcome Skunder | |
Descriptive Information | |
Judul Penelitian Popular | Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older |
Judul Penelitian Ilmiah | Global, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older |
Jenis Penelitian | Interventional |
Intervensi | SARS-CoV02 Messenger Ribonucleic Acid (mRNA) Vaccine |
Jumlah Subyek Penelitian | 5 |
Recruitment Information | |
Eligibility Criteria | Inclusion Criteria: not specifiedExclusion Criteria: not specified |
Administrative Information | |
Nomor Persetujuan Etik | not specified |
Nomor Persetujuan Material Transfer Agreement | Not applicable |
Nomor Persetujuan Pelaksanaan Uji Klinik | PPUK/PPUB number |
Other Study ID Numbers | |
Contact Person | not specified |